<?xml version="1.0" encoding="UTF-8"?>
<p id="Par6">Newborns, premature infants, and those with chronic lung disease are at greater risk of developing severe disease by infection with HRSV [
 <xref ref-type="bibr" rid="CR48">48</xref>]. Despite their importance, there is no vaccine prophylaxis against HRSV infection or effective antiviral therapy available. Currently, in Latin America, only palivizumab (Pz) (Synagis; MedImmune, Gaithersburg, MD, USA) is being used in the prophylaxis and therapy of these infections [
 <xref ref-type="bibr" rid="CR68">68</xref>].
</p>
